While active surveillance is often recommended for patients with nonaggressive prostate cancer to reduce unnecessary treatment, the challenge for clinicians is to monitor and distinguish early-stage tumors from advanced cancers.
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now